tradingkey.logo

Gelteq Ltd

GELS
查看詳細走勢圖
0.897USD
+0.038+4.37%
收盤 12/19, 16:00美東報價延遲15分鐘
9.61M總市值
虧損本益比TTM

Gelteq Ltd

0.897
+0.038+4.37%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.37%

5天

-11.14%

1月

+1.26%

6月

-43.91%

今年開始到現在

-61.31%

1年

-65.35%

查看詳細走勢圖

TradingKey Gelteq Ltd股票評分

單位: USD 更新時間: 2025-10-27

操作建議

當前估值合理,機構持股佔比非常高,目前股價在壓力位和支撐位之間,可以做區間波段操作。

Gelteq Ltd評分

相關信息

行業排名
136 / 173
全市場排名
564 / 4682
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Gelteq Ltd亮點

亮點風險
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
估值高估
公司最新PE估值-2.15,處於3年歷史高位
機構加倉
最新機構持股105.80K股,環比增加0.61%

Gelteq Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Gelteq Ltd簡介

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
公司代碼GELS
公司Gelteq Ltd
CEOGivoni (Nathan Jacob)
網址https://www.gelteq.com

常見問題

Gelteq Ltd(GELS)的當前股價是多少?

Gelteq Ltd(GELS)的當前股價是 0.897。

Gelteq Ltd 的股票代碼是什麼?

Gelteq Ltd的股票代碼是GELS。

Gelteq Ltd股票的52週最高點是多少?

Gelteq Ltd股票的52週最高點是4.110。

Gelteq Ltd股票的52週最低點是多少?

Gelteq Ltd股票的52週最低點是0.770。

Gelteq Ltd的市值是多少?

Gelteq Ltd的市值是9.61M。

Gelteq Ltd的淨利潤是多少?

Gelteq Ltd的淨利潤為-6.65M。

現在Gelteq Ltd(GELS)的股票是買入、持有還是賣出?

根據分析師評級,Gelteq Ltd(GELS)的總體評級為--,目標價格為--。

Gelteq Ltd(GELS)股票的每股收益(EPS TTM)是多少

Gelteq Ltd(GELS)股票的每股收益(EPS TTM)是-1.070。
KeyAI